Content area

|
|

Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Forfatter(e)
Line Bisgaard Jørgensen1, Lars Bastholt2 & Knud Yderstræde1 1) Endokrinologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Odense Universitets-hospital Ugeskr Læger 2017;179:V05170362
Reference: 
Ugeskr Læger 2017;179:V05170362
Blad nummer: 
Sidetal: 
2-6
Immune checkpoint inhibitors and endocrinological side effects
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Skøt Hindrup | 18/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer
af Karin Marlen Moldrup | 13/04
3 kommentarer
af Merete Stampe Mølberg | 13/04
7 kommentarer